UBS Initiates Coverage On Ensysce Biosciences with Buy Rating, Announces Price Target of $2
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Ashwani Verma initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Buy rating and announces Price Target of $2.
UBS analyst Ashwani Verma initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Buy rating and announces Price Target of $2.